Abstract:
La présente invention concerne un composé de formule générale (I) suivante: R 1 -NH-CH(R 2 )-P(=O)(OR 3 )-CH 2 -C(R 4 )(R 5 )-CONH-CH(R 6 )-COOR 7 (I) ou un sel pharmaceutiquement acceptable de celui-ci, un isomère ou un mélange d'isomères en toutes proportions, notamment un mélange d'énantiomères, et en particulier, un mélange racémique, pour laquelle R 1 représente un groupement –C(=O)-O-C(R 8 )(R 9 )-OC(=O)-R 10 ; R 2 représente une chaîne hydrocarbonée éventuellement substituée, un groupe aryle ou hétéroaryle ou un groupe méthylène substitué par un hétérocycle; R 3 représente un atome d'hydrogène ou un groupe–C(R 12 )(R 13 )-OC(=O)-R 14 ; R 4 et R 5 forment ensemble, avec le carbone qui les porte, un cycle hydrocarboné saturé ou un cycle pipéridine éventuellement substitué ou R 4 représente un atome d'hydrogène et R 5 représente un phényle ou un benzyle éventuellement substitué, un cycle hétéroaromatique ou un groupe méthylène substitué par un hétérocycle;R 6 représente une chaîne hydrocarbonée éventuellement substituée ou un phényle ou un benzyle éventuellement substitué; et R 7 représente un atome d'hydrogène ou un groupe benzyle, alkyle, hétéroaryle, alkylhétéroaryle, –CHMe-COOR 18 , -CHR 19 -OC(=O)R 20 et -CHR 19 -OC(=O)OR 20 . La présente invention concerne également l'utilisation de ces composés en tant que médicament, et en particulier pour le traitement de la douleur, plus avantageusement la douleur neuropathique et neuroinflammatoire, leur procédé de synthèse ainsi que les compositions les contenant.
Abstract:
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SlP receptors.
Abstract:
Novel amines of formulas (1D) and (1E), or a pharmaceutically acceptable salt thereof, wherein: n is an integer of from 0 to 2; R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid, or hydroxamic acid; and X is -O-, -S-, -S(O)-, -S(O)2-, or NR'1 wherein R'1 is hydrogen, straight or branched alkyl of from 1 to 6 carbons, or benzyl, -C(O)R'2 wherein R'2 is straight or branched alkyl of 1 to 6 carbons, benzyl or phenyl or -CO2R'3 wherein R'3 is straight or branched alkyl of from 1 to 6 carbons, or benzyl wherein the benzyl or phenyl groups can be unsubstituted or substituted by from 1 to 3 substituents selected from halogen, trifluoromethyl, and nitro, are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders, especially IBS.
Abstract:
Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.
Abstract:
The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups, especially derivatives of TEMPO.
Abstract:
The invention concerns a compound of formula (I), wherein Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is substituted by a group -O-Z and optionally one to three further groups independently represented by R ; Ar2 represents phenyl or 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy; Ar3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkoxy, C1-4 acylamino or an electron withdrawing group; A represents -C(H)-; E represents -C1-6 alkylene-; X represents -CON(H or C1-4alkyl)- or -N(H or C1-4alkyl)CO-;Y represents a direct link, -N(H or C1-4alkyl)CO- or -CON(H or C1-4alkyl)-; Z represents a metabolically labile group; R represents halogen, -S(C1-4alkyl)-, -O-(C0-4 alkylene)-R or -(C0-4alkylene)-R , where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R represents: i) hydrogen, C1-4 perfluoroalkyl, C2-3alkenyl, ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy groups, iii) C3-8cycloalkyl, a 3-7 membered heterocycloalkyl, iv) amino, C1-4 alkylamino or di-C1-4alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms;and physiologically acceptable salts, solvates and pharmaceutical compositions thereof and their use in treating disorders associated with elevated circulating levels of LDL-cholesterol.
Abstract:
Compounds represented by general formula (I), wherein R represents hydrogen, alkyl, substituted alkyl, etc.; R and R each represents hydrogen, alkyl, substituted alkyl, alkoxy, etc.; X represents -CH2-, -O-, or -NH-; A represents a group represented by formula (II)(wherein R and R each represents hydrogen, alkyl, acyl, alkoxycarbonyl, etc.; and R and R each represents hydrogen, halogeno, hydroxy, phenyl, alkyl, etc.), etc.; and E represents hydrogen, etc., or pharmacologically acceptable salts thereof. These compounds have carboxypeptidase B inhibitory activity and are useful for the treatment and/or prevention of thrombotic diseases.
Abstract:
The present invention is directed to pyrrolidine compounds of the formula (I) (wherein R , R , R , R , R , R and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
Abstract:
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
Abstract:
The present application describes prodrugs of the compound of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.